Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook

MT Newswires Live

05/13

Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.

Three analysts polled by FactSet expected 63.09 yen.

Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.

Analysts surveyed by FactSet expected 1.123 trillion yen.

For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2635203042"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2635203042\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2635203042?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-13 15:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2635203042","market":"hk","top_or_hot":-1,"title":"Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook","media":"MT Newswires Live","content":"<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.</p><p>Three analysts polled by FactSet expected 63.09 yen.</p><p>Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.</p><p>Analysts surveyed by FactSet expected 1.123 trillion yen.</p><p>For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Takeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTakeda Pharmaceutical Fiscal Q4 Core Earnings, Revenue Rise; Issues Fiscal 2026 Outlook\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-05-13 15:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.</p><p>Three analysts polled by FactSet expected 63.09 yen.</p><p>Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.</p><p>Analysts surveyed by FactSet expected 1.123 trillion yen.</p><p>For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FXY","symbol_name":"日元ETF-CurrencyShares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2635203042","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2635203042","pubTimestamp":1778656131,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Takeda Pharmaceutical  reported fiscal Q4 core earnings Wednesday of 89 Japanese yen  per share, down from 49 yen a year earlier.Three analysts polled by FactSet expected 63.09 yen.Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.Analysts surveyed by FactSet expected 1.123 trillion yen.For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FXY":"日元ETF-CurrencyShares","HEWJ":"日本ETF汇率对冲-iShares","BK4007":"制药","YCS":"日元ETF-ProShares两倍做空","YCL":"ProShares Ultra Yen","TAK":"武田制药"},"translate_title":"武田制药第四财季核心盈利、收入增长；发布2026财年展望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HEWJ":0.9,"TAK":1,"FXY":0.9,"YCL":0.9,"YCS":0.9},"content_text":"Takeda Pharmaceutical (TAK) reported fiscal Q4 core earnings Wednesday of 89 Japanese yen ($0.56) per share, down from 49 yen a year earlier.Three analysts polled by FactSet expected 63.09 yen.Revenue for the quarter ended March 31 was 1.095 trillion yen, up from 1.052 trillion yen a year earlier.Analysts surveyed by FactSet expected 1.123 trillion yen.For fiscal 2026, the drugmaker expects core EPS of 472 yen and revenue of 4.640 trillion yen. Analysts polled by FactSet are expecting EPS of 497.59 yen and sales of 4.602 trillion yen for the year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}